Longevity & AgingArtículo de investigaciónDe pago

How CD33 splicing shifts microglia toward protection or harm in Alzheimer's disease

A new review shows how CD33 isoform splicing shapes microglial function in Alzheimer's and why it could guide precision therapies.

lunes, 16 de noviembre de 2026 1 visualización
Publicado en Mol Neurobiol
Glowing microglial cell with branching arms engulfing amyloid plaques, CD33 receptors and spliced RNA strands highlighted in blue and amber

Resumen

This review examines CD33, a microglial gene linked by genome-wide studies to Alzheimer's disease risk. CD33 produces two isoforms: the full-length CD33M, described as pro-pathogenic, and the shorter CD33m, described as protective. Genetic variants such as rs3865444 and rs12459419 influence which isoform is made, and splicing factors including hnRNPA/B, PTBP1, and SRSF1 help regulate the process. The authors also discuss how CD33 opposes TREM2, with both converging on DAP12 signaling. They evaluate therapeutic strategies, including isoform-specific immunotherapies, small-molecule splicing modulators, and approaches targeting Siglec-glycan interactions. The authors argue that precision approaches are needed, and they note challenges such as getting drugs across the blood-brain barrier and differences between species. This is a narrative review and does not report new experimental data.

Resumen detallado

Alzheimer's disease involves amyloid-β plaques, tau tangles, and chronic neuroinflammation. Genetic studies point to microglia, the brain's resident immune cells, as central players, and CD33 is one of the most prominent risk genes. Understanding how CD33 works could open new treatment routes beyond targeting amyloid directly.

This paper is a review rather than a primary study. The authors synthesize preclinical and clinical literature on CD33 isoforms: CD33M, described as pro-pathogenic, and CD33m, described as protective. They cover how these forms affect microglial activity, amyloid-β clearance, and inflammatory signaling.

The review describes how isoform production is controlled. Genetic polymorphisms such as rs3865444 and rs12459419 shift splicing, and RNA-binding proteins including hnRNPA/B, PTBP1, and SRSF1 contribute to regulation. The authors also highlight an antagonistic relationship between CD33 and TREM2, with both converging on DAP12 signaling and downstream pathways.

Therapeutic options are evaluated, including isoform-specific immunotherapies, small-molecule splicing modulators, and strategies that disrupt Siglec-glycan interactions. The authors conclude that precision approaches that account for isoform balance are needed to realize CD33's therapeutic potential.

Several caveats apply. Only the abstract was available for this summary, so details of the evidence and its quality are unclear. Reviews can reflect selective literature coverage. The authors themselves flag blood-brain barrier penetration and species-specific discrepancies as obstacles, since mouse models may not fully reflect human CD33 biology. No therapy discussed has been shown here to alter the course of Alzheimer's disease in patients.

Hallazgos clave

  • CD33 yields two isoforms: CD33M is described as pro-pathogenic and CD33m as protective in Alzheimer's microglia.
  • Variants rs3865444 and rs12459419 influence CD33 splicing and isoform balance.
  • hnRNPA/B, PTBP1, and SRSF1 are highlighted as splicing regulators of CD33 isoform formation.
  • CD33 acts antagonistically to TREM2, with both converging on DAP12 signaling pathways.
  • Isoform-specific immunotherapies, splicing modulators, and Siglec-glycan targeting are proposed strategies, limited by blood-brain barrier and species differences.

Metodología

This is a narrative review synthesizing preclinical and clinical literature on CD33 isoforms in Alzheimer's disease. Only the abstract was available, so search methods, inclusion criteria, and quality appraisal are not known.

Limitaciones del estudio

Based on the abstract only, so the strength of the supporting evidence cannot be assessed. As a narrative review, it may be subject to selection bias and presents no new data. The authors note blood-brain barrier delivery and species differences as unresolved challenges for translating CD33 findings.

¿Te ha gustado este resumen?

Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.

Introduce tu correo electrónico para suscribirte: